 Desvenlafaxine succinate DVS SR is a serotonin and norepinephrine reuptake inhibitor SNRI. It is a nonhormonal option for the treatment of Vasomotor Symptoms VMS associated with menopause. Nausea is the most common adverse event that is observed in clinical studies and is the main reason for discontinuation during the first week of therapy. Other adverse events headache, nausea, and dizziness associated with DVS SR have been noted to occur when subjects abruptly discontinue the medication. The purpose of this study is to evaluate several titration and tapering regimens of DVS SR to ensure a better tolerability profile at the start and completion of treatment. In addition, this study will provide a long posttreatment follow-up to assess any symptoms after treatment is discontinued. 